+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Dystrophin - Pipeline Review, H2 2020

  • ID: 5146891
  • Drug Pipelines
  • August 2020
  • Region: Global
  • 128 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Alpha Anomeric
  • Daiichi Sankyo Co Ltd
  • Editas Medicine Inc
  • FibroGenesis LLC
  • Myosana Therapeutics Inc
  • OliPass Corporation
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

According to the recently published report 'Dystrophin - Pipeline Review, H2 2020'; Dystrophin (DMD) pipeline Target constitutes close to 50 molecules. Out of which approximately 44 molecules are developed by companies and remaining by the universities/institutes.

Dystrophin (DMD) - Dystrophin is a cytoplasmic protein. It anchors the extracellular matrix to the cytoskeleton via F-actin. It acts as ligand for dystroglycan. It act as component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma.

The report 'Dystrophin - Pipeline Review, H2 2020' outlays comprehensive information on the Dystrophin (DMD) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Dystrophin (DMD) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 5, 1, 24 and 10 respectively. Similarly, the universities portfolio in Preclinical stages comprises 6 molecules, respectively. Report covers products from therapy areas Genetic Disorders and Musculoskeletal Disorders which include indications Duchenne Muscular Dystrophy, Alport Syndrome and Muscular Dystrophy.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Dystrophin (DMD)
  • The report reviews Dystrophin (DMD) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Dystrophin (DMD) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Dystrophin (DMD) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Dystrophin (DMD) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Dystrophin (DMD)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Dystrophin (DMD) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Alpha Anomeric
  • Daiichi Sankyo Co Ltd
  • Editas Medicine Inc
  • FibroGenesis LLC
  • Myosana Therapeutics Inc
  • OliPass Corporation
  • MORE
Introduction

Report Coverage
  • Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Overview
  • Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • AstraZeneca Plc
  • Avalyn Pharma Inc
  • Boehringer Ingelheim International GmbH
  • Fratagene Therapeutics Srl
  • Lead Discovery Center GmbH
  • Prous Institute for Biomedical Research SA
  • TopiVert Ltd
  • Turning Point Therapeutics Inc
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Drug Profiles
  • bosutinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs to Inhibit SRC for Friedreich Ataxia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ilorasertib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JRP-890 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Dormant Products
  • Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Discontinued Products
  • Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases

Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indications, H2 2020
  • Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by AbbVie Inc, H2 2020
  • Pipeline by AstraZeneca Plc, H2 2020
  • Pipeline by Avalyn Pharma Inc, H2 2020
  • Pipeline by Boehringer Ingelheim International GmbH, H2 2020
  • Pipeline by Fratagene Therapeutics Srl, H2 2020
  • Pipeline by Lead Discovery Center GmbH, H2 2020
  • Pipeline by Prous Institute for Biomedical Research SA, H2 2020
  • Pipeline by TopiVert Ltd, H2 2020
  • Pipeline by Turning Point Therapeutics Inc, H2 2020
  • Dormant Products, H2 2020
  • Dormant Products, H2 2020 (Contd..1), H2 2020
  • Dormant Products, H2 2020 (Contd..2), H2 2020
  • Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Alpha Anomeric
  • Audentes Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Dystrogen Therapeutics SA
  • Editas Medicine Inc
  • Evox Therapeutics Ltd
  • FibroGenesis LLC
  • MyoGene Bio LLC
  • Myosana Therapeutics Inc
  • Nippon Shinyaku Co Ltd
  • OliPass Corporation
  • Pepgen Ltd
  • Pfizer Inc
  • Sarepta Therapeutics Inc
  • Sutura Therapeutics Ltd
  • Tolerion Inc
  • Vertex Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll